Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors
about
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's diseaseTrends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.Medication Adherence in Older Patients With Dementia: A Systematic Literature Review.Living Alone with Alzheimer's Disease: Data from SveDem, the Swedish Dementia Registry.Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions.Persistence With Oral Antihyperglycemic Drugs in Type 2 Diabetes Mellitus Patients With Dementia in Germany.Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany.Persistence with antihypertensives in uncomplicated treatment-naïve very elderly patients: a nationwide population-based study.Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.For how long should we use symptomatic therapies to treat people with Alzheimer disease?Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study.
P2860
Q28076715-69832F39-5135-4E80-ACCA-A45D8050EFC6Q36297147-80B044C9-491A-4962-8FC0-EBA21C955586Q36379356-2CD5F0B7-E00C-43CA-A36F-0F10E464F27DQ36383236-EE8BF35C-32BE-42A0-A568-FDADF584DCF1Q38838575-9F3832BD-E86A-4BD9-AA43-7B93F7E984CCQ38990600-4870DF92-69DD-412B-9F7D-1591ED3EABA5Q39337320-4F5F532A-504B-4636-9345-1B42848E456EQ40133471-5767D7AD-2A5E-49E3-88A3-FA59F6ABE82CQ40260505-6250F573-7605-45A9-BE72-9A9B16C6F1D3Q41520705-623856E4-B88A-4484-8B19-568060D99F99Q42332050-E979436E-47A7-42A4-84EE-44DD054A9F77Q43117191-427CE6A4-536D-47CA-86C6-9DBFF22644EEQ43293526-3E7D87BE-9680-4509-8A6B-7F1B78FA1D77Q50166528-07BE3A10-E0DA-4E32-80D6-DFF30B98D7B3
P2860
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Persistence and adherence with ...... , provider, and system factors
@ast
Persistence and adherence with ...... , provider, and system factors
@en
Persistence and adherence with ...... , provider, and system factors
@nl
type
label
Persistence and adherence with ...... , provider, and system factors
@ast
Persistence and adherence with ...... , provider, and system factors
@en
Persistence and adherence with ...... , provider, and system factors
@nl
prefLabel
Persistence and adherence with ...... , provider, and system factors
@ast
Persistence and adherence with ...... , provider, and system factors
@en
Persistence and adherence with ...... , provider, and system factors
@nl
P2093
P2860
P921
P3181
P1476
Persistence and adherence with ...... , provider, and system factors
@en
P2093
P2860
P304
P3181
P356
10.1177/070674371405901203
P407
P577
2014-12-01T00:00:00Z